跳至主要内容
临床试验/IRCT20230801058996N5
IRCT20230801058996N5尚未招募1 期

Safety and efficacy of placental mesenchymal stem cells-derived exosomes in severe refractory inflammatory bowel disease patients

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 75 years(—)
性别
All

入选标准

  • Ulcerative colitis and/or Crohn's disease for at least 6 months with refractory, or intolerance, or contraindication to use with monoclonal antibodies
  • Highly active Crohn's disease with a Crohn's disease index greater than 450 and/or a simple endoscopic score = 8 (or = 6 for isolated intestinal disease)

排除标准

  • Using common immunomodulators in the past 4 weeks

研究者

相似试验

Mesenchymal stem cells-derived exosomes in severe... | 临床试验